Quarterly report [Sections 13 or 15(d)]

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)

v3.26.1
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
6 Months Ended
Jun. 30, 2026
REVENUES FROM CONTRACTS WITH CUSTOMERS  
Schedule of disaggregation of net revenues

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three-Month Periods Ended June 30, 

​

Six-Month Periods Ended June 30, 

($’s in thousands)

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Emrosi®

​

$

8,074

​

$

2,795

​

$

14,326

​

$

4,865

Qbrexza®

​

​

5,114

​

​

6,949

​

​

10,142

​

​

12,110

Accutane®

​

 

3,358

​

 

3,395

​

 

6,672

​

 

7,050

Foam franchise products (Amzeeq® & Zilxi®)

​

​

941

​

​

1,135

​

​

1,991

​

​

2,661

Eurax®

​

​

120

​

​

—

​

​

120

​

​

—

Other / legacy

​

​

232

​

​

735

​

​

509

​

​

1,462

Total product revenues

​

$

17,839

​

$

15,009

​

$

33,760

​

$

28,148

Schedule of other revenue

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three-Month Periods Ended June 30, 

​

Six-Month Periods Ended June 30,

($’s in thousands)

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Cutia supply agreement

​

$

635

​

$

—

​

$

635

​

$

—

Royalties on sales of Amzeeq by Cutia

​

​

36

​

​

—

​

​

76

​

​

—

Total other revenue

​

$

671

​

$

—

​

$

711

​

$

—